3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Ovarian Neoplasms
1
Mesothelioma
1
Medical Oncology
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Interventions
Gemcitabine
20
Cisplatin
17
pembrolizumab
11
Magnetic Resonance Spectroscopy
7
durvalumab
5
Platinum
5
Irinotecan
5
Fluorouracil
5
1,2-diaminocyclohexaneplatinum II citrate
5
Leucovorin
4
Taxes
3
Oxaliplatin
3
Nivolumab
3
Fluorodeoxyglucose F18
3
Carboplatin
3
Biopsy
3
Bevacizumab
3
spartalizumab
2
pemigatinib
2
ivosidenib
2
fludarabine
2
budigalimab
2
atezolizumab
2
Specimen Handling
2
Radiosurgery
2
Paclitaxel
2
Immunoglobulin G
2
Floxuridine
2
FAPI-46
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Cholangiocarcinoma
×
anetumab ravtansine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled